Australia Oligonucleotide Synthesis Market Size & Outlook
The oligonucleotide synthesis market in Australia is expected to reach a projected revenue of US$ 157.3 million by 2033. A compound annual growth rate of 13.3% is expected of Australia oligonucleotide synthesis market from 2026 to 2033.
Thermo Fisher Scientific Inc, Merck KGaA, GE HealthCare Technologies Inc Common Stock, Agilent Technologies, Kaneka Corp, Heritage Global Inc, Twist Bioscience Corp, Bio-Synthesis, Biolegio
Other key industry trends
In terms of revenue, Australia accounted for 1.6% of the global oligonucleotide synthesis market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Asia Pacific, China oligonucleotide synthesis market is projected to lead the regional market in terms of revenue in 2033.
China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,377.3 million by 2033.
Australia has established and emerging players in the oligonucleotide synthesis market, like Genetic Signatures, Starpharma, and Patrys Limited. These companies are actively researching, developing, and commercializing innovative oligonucleotide-based technologies. Australia has strengths in several areas, such as regenerative medicine and gene editing, where oligonucleotides play a crucial role.
Moreover, the government actively supports developing the biotechnology sector, including oligonucleotide technologies. Funding R&D programs, providing tax breaks for innovative companies, and streamlining regulatory processes are some key initiatives.
Australia Oligonucleotide Synthesis Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Oligonucleotide Synthesis Market Outlook will help companies and investors design strategic landscapes.
Services was the largest segment with a revenue share of 42.3% in 2025.
Horizon Databook has segmented the Australia oligonucleotide synthesis market based on oligonucleotides, equipment/synthesizer, reagents, services covering the revenue growth of each sub-segment from 2021 to 2033.
Australia has established and emerging players in the oligonucleotide synthesis market, like Genetic Signatures, Starpharma, and Patrys Limited. These companies are actively researching, developing, and commercializing innovative oligonucleotide-based technologies. Australia has strengths in several areas, such as regenerative medicine and gene editing, where oligonucleotides play a crucial role.
Moreover, the government actively supports developing the biotechnology sector, including oligonucleotide technologies. Funding R&D programs, providing tax breaks for innovative companies, and streamlining regulatory processes are some key initiatives.
Australia Oligonucleotide Synthesis Market Product Outlook (Revenue, USD Million , 2021-2033)
Oligonucleotides
Equipment/Synthesizer
Reagents
Services
Australia Oligonucleotide Synthesis Market Application Outlook (Revenue, USD Million , 2021-2033)
PCR Primers
PCR Assays and Panels
Sequencing
DNA Microarrays
Fluorescence In Situ Hybridization (FISH)
Antisense Oligonucleotides
Other Applications
Australia Oligonucleotide Synthesis Market End Use Outlook (Revenue, USD Million , 2021-2033)
Academic Research Institutes
Diagnostic Laboratories
Pharmaceutical - Biotechnology Companies
Reasons to subscribe to Oligonucleotide Synthesis Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Oligonucleotide Synthesis Market Outlook databook
Our clientele includes a mix of Oligonucleotide Synthesis Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Oligonucleotide Synthesis Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Oligonucleotide Synthesis Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Australia Oligonucleotide Synthesis Market, 2021-2033 (US$M)